Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives $24.00 Consensus Target Price from Brokerages

Shares of Artelo Biosciences, Inc. (NASDAQ:ARTL) have been assigned a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $24.00.

Several brokerages have recently weighed in on ARTL. Maxim Group reaffirmed a “hold” rating on shares of Artelo Biosciences in a research report on Wednesday, November 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a research report on Monday, December 29th.

Artelo Biosciences Trading Down 1.4%

Shares of ARTL stock opened at $1.40 on Tuesday. The company has a market cap of $2.83 million, a PE ratio of -0.07 and a beta of 1.04. The company’s fifty day simple moving average is $1.69 and its 200-day simple moving average is $6.15. Artelo Biosciences has a 52 week low of $1.15 and a 52 week high of $28.60.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($3.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($3.15). Equities research analysts expect that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.